Common cold products

Marinomed’s first marketed product based on the Carragelose® platform is a cold virus-blocking nasal spray for the prevention and treatment of common cold. The product is a sterile nasal spray that is marketed in the EU and globally in a growing number of countries via renowned partners.

The product is registered as medical device class IIa in Europe since 2007 and is sold as an over-the-counter (OTC) product allowing direct to consumer marketing.

Key claims in EU:

• Can shorten the duration and severity of common cold symptoms
• Can reduce the resurgence of virus-related symptoms of common cold

Claims may vary in non-EU countries dependent on the regulatory status.

Clinical studies were conducted with the virus-blocking nasal spray against common cold, in adults and in small children.

Marinomed has received patents worldwide to protect the Carragelose® platform and its products. Patent protection lasts until end of 2027; the core patent was granted in the EU in 2010.

This product contains two Carragelose® polymers with a total amount of 1,6mg/ml and is specifically designed for the treatment of cold & flu-like illness. The product is a sterile nasal spray that is marketed in the EU and globally in a growing number of countries via renowned partners.

The product is registered as medical device class IIa in Europe and is sold as an over-the-counter (OTC) product allowing direct to consumer marketing.

Key claims in EU:

• Can shorten the duration and severity of flu-like symptoms
• Can reduce the resurgence of virus-related symptoms of a flu-like illness

Carragelose® polymers have shown exceptional activity against human and non-human influenza viruses. For further reading see: Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection, Leibbrandt, et al. 2010, PLoS ONE.

Marinomed has received patents worldwide to protect the Carragelose® platform and its products. Patent protection lasts until end of 2027; the core patent was granted in the EU in 2010.

Carragelose® Lozenges are approved for children and adults above the age of 6 years in the EU. Each lozenge contains 10mg Carragelose®. A typical standard pack contains 2 blisters with 10 lozenges per blister. The lozenges are delivered with a honey-lemon flavor.

The product is registered as medical device class IIa in Europe and is sold as an over-the-counter (OTC) product allowing direct to consumer marketing. The registration status may change in future and might be different in non EU countries

Key claims in EU:

• For accompanying use in the treatment of viral infections of the respiratory tract
• For preventive and sustained moistening of mouth and throat in case of dry breathing air, cough, hoarseness, 

Marinomed has received patents worldwide to protect the Carragelose® platform and its products. Patent protection lasts until end of 2027; the core patent was granted in the EU in 2010.

This product contains Carragelose® with a total amount of 1,2mg/ml and is especially designed for the accompanying treatment of viral infections of the upper respiratory tract. The product is a good treatment option for children who are too small for the use of lozenges.

Key claims in EU:

• For accompanying use in the treatment of viral infections of the respiratory tract
• For the prevention and supportive treatment of all complaints resulting from dry and/or irritated oral and pharyngeal mucosa caused by e.g. smoking, long speaking or singing.

Marinomed has received patents to protect the Carragelose® platform and its products in all important markets including Europe, United States, Japan, Eurasia and many more. Patent protection lasts until end of 2028; the core patent was granted in the EU in 2010.

This formulation has been developed in Marinomed’s laboratories in order to optimize the efficacy of Carragelose® with the addition of a decongestant effect based on increased osmolality. Instead of sodium chloride (NaCl), which also has an osmotic effect, a new formulation is used to retain the activity of Carragelose® against viruses infecting the respiratory tract.

For this product a special IP-protection in addition to the Carragelose® core patents applies and is valid until 2036.

This product in development will combine the virus-blocking effect of Carragelose® with the decongestant effect of the well-known pharmaceutical compound Xylometazoline.